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or chronic bronchitis. The surgery is the primary treatment method with 
reported 5 year survivals of 20-40% for SCC and 60-100% for ACC. 
The role of radiotherapy (RT) has generally been limited to the postop-
erative setting or as the primary modality in unresectable disease. We 
presented 2 patients with ACC treated with curative and postoperative 
chemoradiotherapy. 
Case 1: In February 1998, a 46 years-old female patient applied to 
thoracic surgery in our hospital with 2 months history of dispnea, and 
strong inspiratuary stridor. Ten months before the onset of dyspnea, the 
patient treated as a chronic bronchitis. Roentgenograms and bronchos-
copy showed an tumor ﬁlling more than 80% of the upper level of tra-
cheal lumen extending of 4.5 cm. Histopathological examination with 
biopsy revealed an ACC of trachea. Tumour is adjacent to critically 
organs and too large to permit surgery. 
We treated this patient with a total of 6660 cGy RT and concomitantly 
6 cycles of 30 mg/m2 cisplatin weekly as a lung cancer. At the second 
week, signs and symptoms lost. After four months completion of treat-
ment, complete response was shown radiologically and bronchoscopi-
cally. The patient is living with 106 months. 
Case 2: In May 2003, a 26 years-old male patient was applied to our 
department after the tumor resection and reverse patch tracheoplasty di-
agnosed with ACC of trachea. He had 2 months history of dyspnea and 
hoarseness. MRI showed a large tumor at the level of tyroid cartilage 
and the lenght of the tumor was 3.5 cm. The surgical margin was posi-
tive and there was perineural and lenfatic invasion. He was irradiated 
with a total of 5940 cGy concomitantly 5 cycles of 30 mg/m2 cisplatin 
weekly. The case is living with 43 months. 
Conclusion: Malign tracheal tumors are extremely rare. We report 2 
cases with tracheal tumors of whom presented with a 2 months history 
of dyspnea, stridor and failure to thrive. Radiation therapy has a role 
in the treatment of tracheal malignancy, either as postoperative or as 
primary therapy for medically inoperable disease. Alternative methods 
such as concomitant radiosensitizer for increasing local administration 
of RT, should be investigated for improvement in local control. 
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Background: The most active regimens in MPM include cisplatin and 
also vinorelbine is among the most active agents, though not extensive-
ly evaluated in this disease. Hence, the aim was to evaluate a combina-
tion of these two agents as ﬁrst line treatment in non-resectable MPM.
Methods: Previously untreated pts with histologically veriﬁed MPM, 
normal renal-, hepatic-, and bone marrow function and performance 
status 0-2 were included. There was no upper age limit. Patients 
received vinorelbine 25 mg/m2 i.v. weekly and cisplatin 100 mg/m2 i.v. 
every four weeks for a maximum of six cycles. Hydration and standard 
prophylactic antiemetic treatment was given. Pts gave written informed 
consent.
Results: A total of 57 consecutive patients were entered from 02/2003 
to 01/2006. Characteristics were: Males 83%, epithelial subtype 76%, 
IMIG stages I, II, III, and IV 4%, 14%, 35%, and 47%, performance 
status 0 1, and 2 25%, 70%, and 5%, and median age 63 yrs (31-78 
yrs). CTC grade 3 or 4 toxicity occurred with respect to leucocytopenia 
(47% of pts, grade 4 in 12%), nausea (14%), neurotoxicity (5%), neph-
rotoxicity (4%), and other toxicities (9%). There were no toxic deaths. 
Median no. of cycles was 4. The fraction of patients alive at 1-, 2-, and 
3-yrs were 49%, 23%, and 4%, respectively, and median survival was 
11.6 mths (0.5-41.7+mths). There were one CR and 15 PRs, response 
rate 28% (95% conﬁdence limits 17%-42%), with median response 
duration of 3.8 mths (1.6-36.2 mths). Second-line chemotherapy was 
given to 39% of patients.
Conclusions: Cisplatin and intraveneous vinorelbine is a highly active 
regimen in MPM with a response rate and survival comparable to the 
most active regimens so far reported, quality of life for the regimens 
should however be compared. Hematologic toxicity was moderate and 
the regimen is feasible without any toxic death. The regimen may be 
simpliﬁed by use of oral vinorelbine. 
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Background: The most active regimens in MPM include cisplatin 
together with another active agent such as pemetrexed, raltitrexed, or 
gemcitabine. Cisplatin has in many trials been substituted by carbopla-
tin for more easy administration and milder toxicity. Also vinorelbine is 
among the most active agents, though not extensively evaluated in this 
disease. A combination of cisplatin and i.v. vinorelbine has previously 
shown response rate of 28% and median survival of 11.6 months which 
is comparable to the most active regimens in MPM. The purpose of this 
trial was to evaluate the activity of a more feasible regimen of carbo-
platin together with vinorelbine administered i.v. and orally.
Methods: Previously untreated pts with non-resectable histologically 
veriﬁed MPM, normal renal-, hepatic-, and bone marrow function and 
performance status 0-2 were included. There was no upper age limit. 
Patients received carboplatin AUC 5 (Calvert formula) i.v. every three 
weeks together with vinorelbine 25 mg/m2 i.v. day one and 60-80 mg/
m2 orally day 8 in each cycle (60 mg/m2 in ﬁrst cycle, then 80 mg/m2 in 
subsequent cycles pending it was well-tolerated) for a maximum of six 
cycles. Standard prophylactic antiemetic treatment was given. Patients 
gave written informed consent.
Results: A total of 27 consecutive patients were entered from 08/2005 
to 03/2007. Characteristics were: Males 89%, epithelial subtype 67%, 
asbestos exposure 81%, IMIG stages II, III, and IV 11%, 48%, and 
41%, performance status 0, 1, and 2 19%, 59%, and 22%, respec-
tively, and median age 69 yrs (56-79 yrs). CTC grade 3 or 4 toxicity 
occurred only with respect to leucocytopenia (63% of pts, grade 4 in 
15%). There were 7 cases of febrile leucocytopenia but no toxic deaths. 
Median no. of cycles was 5 (range 1-6). Eleven patients have expired 
while 16 are alive; the median survival is not yet reached, being in 
excess of 9 months. Five PRs have been recorded, response rate 19% 
(95% conﬁdence limits 6%-38%). Second-line chemotherapy was 
given to 22% of patients.
